US reference laboratory completes ASTar® evaluation

Q-linea AB (publ) (OMX:QLINEA) today announces that a US reference laboratory has completed their analytical evaluation of the ASTar instrument and Gram-negative blood culture panel.

The company is now in discussions with the reference laboratory leadership regarding next steps for implementation of ASTar for routine clinical use. Additional evaluations are ongoing at several US academic medical centers.

Interest in adoption and implementation of the ASTar system continues to grow due to the fully automated nature of the instrument, low hands-on time, high throughput, and ease of use.

Previous communication (May 2nd): https://qlinea.com/mfn_news/q-linea-signs-evaluation-contract-with-reference-laboratory-network-in-the-us/?ln=en

For more information, please contact:

Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com
+1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20

About Q-linea

Q-linea's rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.
Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.
ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

Attachments

US reference laboratory completes ASTar® evaluation